Company profile

Wyche Thomas Green
Incorporated in
Fiscal year end
Former names
Lanvision Systems Inc, Streeamline Health Solutions Inc.
IRS number

STRM stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


12 Sep 19
22 Nov 19
31 Jan 20


Company financial data Financial data

Quarter (USD) Jul 19 Apr 19 Jan 19 Oct 18
Revenue 4.79M 5.36M 5.37M
Net income -608K 313K -3.1M -678.51K
Diluted EPS -0.03 0.01 -0.16 -0.03
Net profit margin -12.69% 5.84% -12.64%
Operating income -433K 434K -2.99M -545.88K
Net change in cash -780K -367K 1.23M -2.1M
Cash on hand 1.23M 2.01M 2.38M 1.14M
Cost of revenue 223.24K
Annual (USD) Jan 19 Jan 18 Jan 17 Jan 16
Revenue 22.37M 24.34M 27.06M 28.31M
Net income -5.87M -3.1M -5.16M -4.29M
Diluted EPS -0.3 -0.16 -0.31 -0.3
Net profit margin -26.22% -12.73% -19.07% -15.15%
Operating income -5.3M -2.62M -4.77M -5.62M
Net change in cash -2.24M -1.03M -4.23M 3.36M
Cash on hand 2.38M 4.62M 5.65M 9.88M
Cost of revenue 2.4M 2.72M 3.14M

Financial data from company earnings reports

Financial report summary

  • Our sales have been concentrated in a small number of clients.
  • A significant increase in new SaaS contracts could reduce near term profitability and require a significant cash outlay, which could adversely affect near term cash flow and financial flexibility.
  • Our eValuator platform, coding audit services and associated software and technologies represent a relatively new market for the Company, and we may not see the anticipated market interest or growth due to being a new player in the industry.
  • Clients may exercise termination rights within their contracts, which may cause uncertainty in anticipated and future revenue streams.
  • Changes in healthcare regulations impacting coding, payers and other aspects of the healthcare regulatory cycle could have substantial impact on our financial performance, growth and operating costs.
  • The potential impact on us of new or changes in existing federal, state and local regulations governing healthcare information could be substantial.
  • The healthcare industry is highly regulated. Any material changes in the political, economic or regulatory healthcare environment that affect the group purchasing business or the purchasing practices and operations of healthcare organizations, or that lead to consolidation in the healthcare industry, could require us to modify our services or reduce the funds available to providers to purchase our solutions and services.
  • We face significant competition, including from companies with significantly greater resources.
  • The healthcare industry is evolving rapidly, which may make it more difficult for us to be competitive in the future.
  • Rapid technology changes and short product life cycles could harm our business.
  • Our intellectual property rights are valuable, and any inability to protect them could reduce the value of our solutions and services.
  • We could be subjected to claims of intellectual property infringement that could be expensive to defend.
  • Over the last several years, we have completed a number of acquisitions and may undertake additional acquisitions in the future. Any failure to adequately integrate past and future acquisitions into our business could have a material adverse effect on us.
  • Third-party products are essential to our software.
  • Our solutions may not be error-free and could result in claims of breach of contract and liabilities.
  • We could be liable to third parties from the use of our solutions.
  • Our SaaS and support services could experience interruptions.
  • Our SaaS solutions are provided over an internet connection. Any breach of security or confidentiality of protected health information could expose us to significant expense and harm our reputation.
  • The loss of key personnel could adversely affect our business.
  • Our future success depends upon our ability to grow, and if we are unable to manage our growth effectively, we may incur unexpected expenses and be unable to meet our clients’ requirements.
  • We may not have access to sufficient or cost-efficient capital to support our growth, execute our business plans and remain competitive in our markets.
  • We previously entered into a software license and royalty agreement with Montefiore Medical Center pursuant to which we are obligated to pay Montefiore $1,000,000 in cash by July 31, 2020. The payment of this obligation could adversely affect our business.
  • Potential disruptions in the credit markets may adversely affect our business, including the availability and cost of short-term funds for liquidity requirements and our ability to meet long-term commitments, which could adversely affect our results of operations, cash flows and financial condition.
  • We must maintain compliance with the terms of our existing credit facilities or receive a waiver for any non-compliance. The failure to maintain compliance could have a material adverse effect on our ability to finance our ongoing operations and we may not be able to find an alternative lending source if a default occurs.
  • If we are unable to repay, extend or refinance our existing and future debt as it becomes due on terms reasonably acceptable to us, or at all, we may be unable to continue as a going concern.
  • Our outstanding preferred stock have significant redemption and repayment rights that could have a material adverse effect on our liquidity and available financing for our ongoing operations.
  • Economic conditions in the U.S. and globally may have significant effects on our clients and suppliers that could result in material adverse effects on our business, operating results and stock price.
  • The variability of our quarterly operating results can be significant.
  • The preparation of our financial statements requires the use of estimates that may vary from actual results.
  • Failure to improve and maintain the quality of internal control over financial reporting and disclosure controls and procedures or other lapses in compliance could materially and adversely affect our ability to provide timely and accurate financial information about us or subject us to potential liability.
  • Our operations are subject to foreign currency exchange rate risk.
  • The market price of our common stock is likely to be highly volatile as the stock market in general can be highly volatile.
  • If equity research analysts do not publish research reports about our business or if they issue unfavorable commentary or downgrade our common stock, the price of our common stock could decline.
  • All of our debt obligations, our existing preferred stock and any preferred stock that we may issue in the future will have priority over our common stock with respect to payment in the event of a bankruptcy, liquidation, dissolution or winding up.
  • There may be future sales or other dilution of our equity, which may adversely affect the market price of our common stock.
  • In addition to our currently outstanding preferred stock, the issuance of an additional series of preferred stock could adversely affect holders of shares of our common stock, which may negatively impact your investment.
  • We do not currently intend to pay dividends on our common stock and, consequently, your ability to achieve a return on your investment will depend solely on appreciation in the price of our common stock.
  • Sales of shares of our common stock or securities convertible into our common stock in the public market may cause the market price of our common stock to fall.
  • If we are unable to maintain compliance with Nasdaq listing requirements, our stock could be delisted, and the trading price, volume and marketability of our stock could be adversely affected.
Management Discussion
  • Proprietary software and term licenses — Proprietary software revenue recognized for the three and six months ended July 31, 2019 decreased by $107,000 and $944,000, respectively, over the prior comparable periods. As previously reported, perpetual license sales are less predictable from a timing standpoint than other solutions sold by the Company.   This decrease is attributable to a large perpetual license sale of our Abstracting™ solution in the first quarter of fiscal 2018.  The Company is able to influence sales of these products; however, the timing can be difficult to manage as sales result from our distribution partners or our direct channel from existing customers adding licenses from acquisitions or strategic partnerships. The timing can be difficult to manage because we do not control our distribution partners, and their sense of urgency on closing perpetual licenses and we do not control our existing customers adding facilities through acquisition or strategic partnerships.  The Company is expecting higher perpetual license sales in the third and fourth quarter of fiscal 2019.   We believe this is supported by the Company’s pipeline, however, the timing is different from fiscal year 2018.   Term license revenue recognized for the three and six months ended July 31, 2019 decreased by $95,000 and $138,000, respectively, over the prior comparable periods due to lost customers.  Term license revenue is expected to be higher in the third and fourth quarters of fiscal 2019, but not to the levels of fiscal 2018.   
Content analysis ?
H.S. sophomore Avg
New words: ago, CEO, Chairman, description, entirety, evidence, evidenced, exhibit, Green, kind, leadership, LLC, lost, payer, PIK, pipeline, placement, prioritized, purport, refrain, retention, sense, standpoint, Tee, therewith, urgency, Wyche
Removed: delayed, revaluation